Immunovant Inc

$15.66
(as of Jun 13, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Immunovant Inc

Stock Price
$15.66
Ticker Symbol
IMVT
Exchange
NASDAQ

Industry Information for Immunovant Inc

Sector
Healthcare
Industry
Biotechnology

Company Description for Immunovant Inc

Website
https://immunovant.com
Country
USA
Full Time Employees
362

Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for graves' disease and thyroid eye disease. The company has a license agreement with HanAll Biopharma Co., Ltd. for the rights of intellectual property relating to IMVT-1402 and batoclimab. Immunovant, Inc. was founded in 2018 and is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

Fundamentals for Immunovant Inc

Market Capitalization
$2,724,511,232
EBITDA
$-437,775,008
Dividends per Share
P/E Ratio
Forward P/E Ratio
0
Earnings per Share
$-2.73
Earnings per Share Estimate Next Year
Profit Margin
Shares Outstanding
170,923,008
Percent Owned by Insiders
58.37%
Percent Owned by Institutions
55.82%
52-Week High
52-Week Low

Technical Indicators for Immunovant Inc

50-Day Moving Average
200-Day Moving Average
RSI
ATR
0.85

Analyst Ratings for Immunovant Inc

Strong Buy
10
Buy
3
Hold
1
Sell
0
Strong Sell
0

News About Immunovant Inc

Jun 5, 2025, 6:23 AM EST
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. See more.
Jun 2, 2025, 12:00 PM EST
Immunovant, Inc. See more.
May 30, 2025, 8:59 AM EST
Immunovant, Inc. See more.
May 29, 2025, 7:13 AM EST
* Immunovant press release [https://seekingalpha.com/pr/20119506-immunovant-provides-corporate-updates-and-reports-financial-results-for-the-fourth-quarter] (NASDAQ:IMVT [https://seekingalpha.com/symbol/IMVT]): Q4 GAAP EPS of -$0.64 beats by $0.06. See more.